不同尿素氮水平尿毒血清对人脐静脉内皮细胞的影响

目的:观察不同BUN水平尿毒血清对体外培养人脐静脉内皮细胞(HUVEC)的影响,并探讨尿毒症患者动脉粥样硬化发病的可能机制.方法:比色法测定HUVEC上清液NO、MDA的水平;免疫细胞化学法测定胞浆iNOS表达;酶联免疫吸附法(ELISA)测定上清液iNOS蛋白水平.结果:尿毒血清各组均可上调HUVEC的MDA生成,且以BUN≥50 mmol/L的尿毒血清组对MDA上调最明显(P<0.01);尿毒血清各组可下调HUVEC的NO生成,呈BUN浓度依赖性关系(P<0.01);尿毒血清各组可激活HUVEC的iNOS,诱导细胞生成大量NO,但随着BUN水平的升高,NO、iNOS呈下降趋势,BUN≥50 mmol/L尿毒血清组下降显著(P<0.01).结论:尿毒血清对HUVEC有毒性作用,呈BUN浓度依赖性关系,尤其是BUN≥50 mmol/L时,细胞损伤更为加重.     

尾加压素对新生大鼠心肌细胞一氧化氮合成的影响

应用半定量逆转录－多聚酶链反应法,观察尾加压素（urotensin Ⅱ,UⅡ）对培养的新生SD大鼠心肌细胞内皮型一氧化氮合酶（endothelial nitric oxide synthase,eNOS)mRNA表达的影响,并测定UⅡ对心肌细胞内一氧化氮合酶（nitric oxide synthase,NOS)活性和一氧化氮（nitric oxide,NO)释放的影响。结果显示：UⅡ抑制培养的新生大鼠心肌细胞eNOS mRNA表达、抑制NOS的活性及NO释放;0.1μmol/L浓度的UⅡ呈时间依赖性抑制心肌细胞NOS的活性及NO生成。上述实验结果提示UⅡ的心血管作用可能与NO合成系统有关。     

尾加压素Ⅱ及其生物学效应

尾加压素Ⅱ（urotensinⅡ,UⅡ)最早是从鱼尾部下垂体中分离出的调节肽,近来已从人体中克隆出来,并发现体内一种孤立的Ｇ蛋白偶联受体ＧＰＲ１４是其特异性受体,主要分布于心血管与神经系统,ＵⅡ与ＧＰＲ１４结合后,引起细胞内Ｃa^2 浓度增高,参与许多生物学效应,如调节内分泌效应,调节渗透压平衡,调节胃肠道平滑肌及心血管收缩功能等,是迄今体内最强的缩血管活性肽。     

人尾加压素Ⅱ对大鼠脑微循环的影响

目的:探讨尾加压素Ⅱ(UII)对于大鼠软脑膜微循环的影响.方法:健康成年SD大鼠随机分为对照组、生理盐水(NS)、UII(10-7mol/L)、去甲肾上腺素(NA,10-6mol/L)、UII(10-7mol/L) NA(10-6mol/L)等五组,采用活体微循环观测技术观察大鼠软脑膜微血管内径、血流速度等微循环参数,采用激光多普勒血流量仪测定软脑膜血流量的变化.结果:正常对照组软脑膜细动脉和细静脉血管内径分别为(35.4±3.6)μm和(40.6±8.5)μm,UII组于滴加UII(10-7mol/L)后即刻细动脉和细静脉出现收缩,1 min时细动脉和细静脉收缩达到高峰,血管内径分别为(25.6±3.4)μm和(23.4±3.3)μm (与正常对照组比较,P均<0.05);细动、静脉内血流速度无明显变化(与正常对照组比较P均>0.05);软脑膜血流量于滴加UII(10-7mol/L)后1 min开始升高,5 min达到高峰(3.5±0.4 )PU 值,正常对照组(2.3±0.6)PU值(P<0.05).结论:UII可以使大鼠软脑膜微血管收缩,血流量增加.     

高肺血流对大鼠肺血管结构及尾加压素Ⅱ表达的影响

目的：探讨新型血管活性肽人类尾加压素Ⅱ(hUⅡ)在高肺血流量所致肺动脉高压大鼠肺动脉中的表达及其作用。方法：对大鼠行腹主动脉-下腔静脉分流术。11周后,以右心导管法测肺动脉压力,观测肺血管显微结构的变化,以免疫组织化学方法检测肺动脉hUⅡ的表达。结果：分流术后11周,大鼠肺动脉高压形成,肺小血管肌化程度明显增强,肺中、小型肌型动脉相对中膜厚度明显增加。分流组大鼠肺动脉内皮细胞和平滑肌细胞hUⅡ蛋白表达上调,并且与肺动脉压力和肺血管结构的改变呈正相关。结论：肺动脉内皮细胞和平滑肌细胞hUⅡ的上调可能参与了高肺血流量所致肺血管结构重建和肺动脉高压的形成。     

糖皮质激素对机械通气大鼠肺组织iNOS、NO表达的影响

目的通过观察糖皮质激素对机械通气大鼠肺组织诱导型一氧化氮合酶（iNOS）及一氧化氮（NO）表达的影响,探讨糖皮质激素对呼吸机所致肺损伤（ventilator induced lung injury,VILI）的干预作用。方法 24只雄性Wistar大鼠随机分为对照组、机械通气组、地塞米松（DXM）干预组。用逆转录-聚合酶链反应（RT-PCR）法检测肺组织iNOS mRNA表达,用免疫组织化学染色法检测肺组织iNOS蛋白表达,用硝酸还原酶法测定肺组织和血浆NO含量。结果机械通气组和DXM干预组大鼠肺组织iNOS mRNA及其蛋白表达水平,以及血浆和肺组织NO含量均明显高于对照组（P〈0.01）;DXM干预组上述指标与机械通气组比较均明显降低（P〈0.01）。结论糖皮质激素可通过抑制肺组织iNOS的表达,减少NO的生成,对机械通气大鼠肺组织具有保护作用。     

异丙酚对全脑缺血倡灌注大鼠海马iNOS表达的影响

目的：观察异丙酚对全脑缺血／再灌注大鼠海马神经元诱导型一氧化氮合酶（iNOS）表达的影响,探讨异丙酚对迟发性脑神经元损伤保护作用机制。方法：采用Pulsinelli-Brierley四血管阻断法制备全脑缺血模型。全脑缺血20rain再灌注24h后断头取脑,采用Western blot方法检测大鼠海马iNOS的蛋白表达。结果：与缺血／再灌注组相比较,异丙酚处理组大鼠海马iNOS蛋白表达明显降低,存活的神经元数目明显增加,统计结果差异均有显著性（P〈0.05或0.01）。结论：异丙酚通过抑制iNOS蛋白表达对大鼠脑迟发性神经元损伤起保护作用。     

人尾加压素Ⅱ在心血管疾病中的作用

尾加压素Ⅱ（UrotensinⅡ,UⅡ）是具有广泛生物学效应的活性肽,发现其在高血压、动脉粥样硬化、心衰、肾脏疾病、糖尿病等疾病的发生、发展中具有十分重要的意义。本文就近年其对心血管系统作用的研究进展作一综述。     

尾加压素Ⅱ相关肽--新发现的尾加压素Ⅱ受体的内源性配体

尾加压素Ⅱ(urotensinⅡ,UⅡ)最早是从鱼的脊髓中分离出来的生长抑素样环肽,是目前所知最强的缩血管活性物质。随后,Ames等发现人体内一种孤立的G蛋白偶联受体GPR14是UⅡ的特异性受体。2003年Sugo T等在大鼠脑组织提取物中监测UⅡ的免疫反应性时,分离出一种新的活性多肽并命名为尾加压素Ⅱ相关肽(urotensin Ⅱrelated peptide,URP),其氨基酸序列为ACFWKYCV,在半胱氨酸之间由二硫键连接,与UⅡ有着相同的CFWKYC结构。     

异丙酚对全脑缺血/再灌注大鼠海马iNOS表达的影响

目的观察异丙酚对全脑缺血/再灌注大鼠海马神经元诱导型一氧化氮合酶(iNOS)表达的影响,探讨异丙酚对迟发性脑神经元损伤保护作用机制。方法采用Pulsinelli-Brierley四血管阻断法制备全脑缺血模型。全脑缺血20min再灌注24h后断头取脑,采用Western blot方法检测大鼠海马iNOS的蛋白表达。结果与缺血/再灌注组相比较,异丙酚处理组大鼠海马iNOS蛋白表达明显降低,存活的神经元数目明显增加,统计结果差异均有显著性(P<0.05或0.01)。结论异丙酚通过抑制iNOS蛋白表达对大鼠脑迟发性神经元损伤起保护作用。     

Proteoglycans from human umbilical vein endothelial cells

Human umbilical vein endothelial cells were incubated with [35S]sulphate and investigated for their proteoglycan production. By gel chromatography, ion-exchange chromatography and CsCl density-gradient centrifugation we obtained preparative amounts of the endothelial proteoheparan sulphate HSI and of proteochondroitin sulphate from the conditioned medium of mass-cultured human umbilical vein endothelial cells. Approximately 90% of the 35S-labeled material in the endothelial cell conditioned medium was proteochondroitin sulphate. This molecule, with a molecular mass of 180-200 kDa, contains four side-chains of 35-40 kDa and a core protein of 35-40 kDa. Two proteoheparan sulphate forms (HSI and HSII) from the conditioned medium were distinguished by molecular mass and transport kinetics from the cell layer to the medium in pulse-chase experiments. One major form (HSI), with an approximate molecular mass of 160-200 kDa a core protein of 55-60 kDa and three to four polysaccharide side-chains of 35 kDa each, was found enriched in the cellular membrane pellet. Another proteoheparan sulphate (HSII), with polysaccharide moieties of 20 kDa, is enriched in the subendothelial matrix (substratum).     

Effect of apple extracts on NF-kappaB activation in human umbilical vein endothelial cells

The mechanisms by which foods, such as fruit, are able to reduce the risk of chronic disease are still unclear. Several fruit products, including apples and apple juice, that are flavonoid-rich are reported to increase antioxidant levels in human subjects. This is supported by the finding from our previous studies that the chronic consumption of apple juice by human subjects reduced ex vivo low-density lipoprotein (LDL) oxidation; we hypothesized that this was due to the flavonoid in the apple juice, which, as we reported earlier, reduced in vitro LDL oxidation. To further explore whether the mixture of flavonoids and other phytochemicals in apples are biologically relevant antioxidants, we tested the effects of this flavonoid-rich apple extract (AE) on oxidant-related pathways in a model of the endothelium: human umbilical vascular endothelial cells (HU-VECs). The effects of AE on oxidant-responsive (i.e., tumor necrosis factor [TNF]-alpha-induced) nuclear factor (NF)- kappaB signaling in cell culture were assessed in transfected HUVECs by using a construct that expressed luciferase under the control of NF-kappaB. Incubation of HUVEC for 24 hrs with up to 10 mM (as gallic acid equivalents) of AE demonstrated no cytotoxicity, as determined by lactate dehydrogenase release, caspase 3 activation, and apoptosis marker-based FACS analysis. AE after a 24-hr incubation period at either 200 or 2000 nM showed a complex pattern of decreased basal and TNF-alpha-stimulated NF-kappaB signaling (63% maximal decrease) as assessed by luciferase activity in the transfected HUVECs, as well as by reduced levels of IkappaBalpha protein phosphorylation detected by Western blot analysis. We suggest that AE downregulates NF-kappaB signaling and that this is indicative of an antioxidant effect of the flavonoids present in AE.     

The expression of high molecular weight kininogen on human umbilical vein endothelial cells

High molecular weight kininogen (HMWK) functions as a cofactor for activation of plasma serine zymogens and as an inhibitor of tissue cysteine proteases. Cell surfaces to which HMWK binds may provide sites for regulation of these systems. Localization of these HMWK-dependent processes at sites of vascular injury may depend on its binding to specific receptors on endothelial cells. In culture, passaged human umbilical vein endothelial cells (HUVEC) bind anti-HMWK antibody to the cell surface and contain 171 +/- 75 ng of HMWK/10(8) cells. [35S]Methionine-labeled HUVEC in culture synthesize a 120-kDa protein immunoisolated using an anti-kininogen antibody, and a 3500-nucleotide message for human HMWK was detected by Northern blot in RNA extracted from HUVEC. HUVEC also express unoccupied binding sites for HMWK on their surface. 125I-HMWK specifically binds to HUVEC in a reaction requiring Zn2+. 125I-HMWK binding to HUVEC is saturable at 4 degrees C but not at 23 degrees C. 125I-HMWK binds to HUVEC with equal affinity as unlabeled HMWK. Kallikrein, factor XII, fibrinogen, fibronectin, and thrombin do not inhibit 125I-HMWK binding to HUVEC. 125I-HMWK-HUVEC binding remains fully reversible at 60 min following the addition of a 50-fold molar excess HMWK. HUVEC express 9.3 +/- 2.0 X 10(5) (mean +/- S.E.) HMWK binding sites/cell (Kd = 52 +/- 13 nM). Both added and cell-bound 125I-HMWK migrate at 120 kDa on sodium dodecyl sulfate gel electrophoresis, suggesting that the protein remains uncleaved upon binding to the HUVEC surface. These studies indicate that HUVEC synthesize HMWK and the HUVEC surface has a site for its expression. By synthesizing and localizing HMWK to the cell surface, endothelial cells may contribute to the activation of plasma's contact serine zymogens and regulation of tissue cysteine proteases.     

Organizational behavior of human umbilical vein endothelial cells

Culture conditions that favor rapid multiplication of human umbilical vein endothelial cells (HUV-EC) also support long-term serial propagation of the cells. This is routinely achieved when HUV-EC are grown in Medium 199 (M-199) supplemented with fetal bovine serum (FBS) and endothelial cell growth factor (ECGF), on a human fibronectin (HFN) matrix. The HUV-EC can shift from a proliferative to an organized state when the in vitro conditions are changed from those favoring low density proliferation to those supporting high density survival. When ECGF and HFN are omitted, cultures fail to achieve confluence beyond the first or second passage: the preconfluent cultures organize into tubular structures after 4-6 wk. Some tubes become grossly visible and float in the culture medium, remaining tethered to the plastic dish at either end of the tube. On an ultrastructural level, the tubes consist of cells, held together by junctional complexes, arranged so as to form a lumen. The smallest lumens are formed by one cell folding over to form a junction with itself. The cells contain Weibel-Palade bodies and factor VIII-related antigen. The lumens contain granular, fibrillar and amorphous debris. Predigesting the HFN matrix with trypsin (10 min, 37 degrees C) or plasmin significantly accelerates tube formation. Thrombin and plasminogen activator had no apparent effect. Disruption of the largest tubes with trypsin/EDTA permits the cells to revert to a proliferative state if plated on HFN, in M-199, FBS, and ECGF. These observations indicate that culture conditions that do not favor proliferation permit attainment of a state of nonterminal differentiation (organization) by the endothelial cell. Furthermore, proteolytic modification of the HFN matrix may play an important role in endothelial organization.     

Silymarin inhibits TNF-alpha-induced expression of adhesion molecules in human umbilical vein endothelial cells

Silymarin is known to have an anti-atherosclerotic activity, but the mechanism responsible for it remains unclear. Here, we demonstrate a possible mechanism involved in the anti-atherosclerotic activity of silymarin. Silymarin inhibited THP-1 cell adhesion to human umbilical vein endothelial cells (HUVECs). Silymarin also suppressed the TNF-alpha-induced protein and mRNA expression of adhesion molecules, such as VCAM-1, ICAM-1 and E-selectin, in HUVECs. Moreover, silymarin suppressed the TNF-alpha-induced DNA binding of NF-kappaB/Rel in HUVECs. Taken together, these results demonstrate that silymarin exerts an anti-atherosclerotic activity, at least in part, by inhibiting the expression of adhesion molecules.     

Effect of estradiol and dihydrotestosterone on hypergravity-induced MAPK signaling and occludin expression in human umbilical vein endothelial cells

Female astronauts have been reported to have a higher incidence of post-flight orthostatic intolerance (POI) compared with that of their male counterparts. POI may result from increased permeability of the endothelial cell (EC) layer in the vasculature. The goal of this study has been to determine whether estradiol (E₂) and dihydrotesterone (DHT) alter human umbilical vein ECs (HUVECs) responses to short term (10 min) hypergravity (1–3 g) mimicking the g force experienced by astronauts during liftoff. E₂ and DHT rapidly (within 5 min) activated MAPK (mitogen-activated protein kinase) in HUVEC at 1 g in a receptor-dependent manner. Liftoff inhibited MAPK phosphorylation, and rapid E₂ and DHT activation of MAPK was blocked. Liftoff simulation or brief (5–90 min) treatment with E₂ or DHT at 1 g had no effect on the expression of the EC tight-junction protein occludin. However, 24-h pre-treatment of HUVECs with E₂ and DHT prior to liftoff simulation significantly increased occludin expression, and hypergravity exposure did not alter this increase. These data provide evidence for a possible protective effect of E₂ and DHT on EC function as indicated by increased occludin; this may help maintain the integrity of EC tight junction and could thus retard or reduce the incidence of POI.This work was supported by NASA grant NAG5-12874 to C.M.K. and R.S.K. and by American Heart Association Ohio Valley Affiliate grant 0555270B to C.M.K. The American Heart Association Ohio Valley supported W.K.S. with an affiliate post-doctoral fellowship (0425431B).     

Recombinant gene expression in human umbilical vein endothelial cells transduced by retroviral vectors

Endothelial cells are attractive targets for gene transfer because of their immediate contact with the bloodstream, and, therefore, they might serve as vehicles for therapeutic drug delivery. Recently, we and others reported that endothelial cells of animal origin efficiently express both secretory and nonsecretory recombinant proteins. We now show that human endothelial cells are also capable of expressing a recombinant gene following transduction with retroviral vectors. Human umbilical vein endothelial cells were transduced with either the N2 or the SAX vector. Following selection with G418, cells transduced by both vectors were found to express neophosphotransferase activity, the product of the neomycin resistance gene. The fact that a recombinant gene can be readily inserted and efficiently expressed into human endothelial cells suggests that these cells may be able to serve a role in human gene therapy.     

Antiapoptotic effect of ouabain on human umbilical vein endothelial cells

The present study investigates the effect of ouabain on caspase-3 activation in human umbilical vein endothelial cells (HUVEC). Ouabain (EC(50) 20 nM) reduced caspase-3 activity in HUVEC treated for 24h in a medium deprived of fibroblast growth factor (FGF). Incubation for 5h in the absence of both FGF and serum produced an increase in caspase-3 activity that was completely abolished by 100 nM ouabain. Pretreatment with the phosphatidylinositol 3 kinase (PI-3K) inhibitor, wortmannin, prevented the protective effect of ouabain against serum deprivation. Furthermore, Western blotting analysis revealed an increase in phosphorylation of extracellular signal-regulated kinases (ERK-1 and ERK-2) induced by 100nM ouabain in serum-deprived cells. In accord, pretreatment of HUVEC with PD98059, inhibitor of the ERK pathway, abrogated the effect of ouabain. Our results show that ouabain has an antiapoptotic effect on HUVEC through the activation of PI-3K and ERK dependent pathways.